CEP55 (Centrosomal Protein 55) is a key regulator of cell division, primarily involved in cytokinesis and centrosome duplication. It localizes to the centrosome during interphase and relocates to the midbody during mitosis, facilitating the final separation of daughter cells. CEP55 interacts with proteins like ALIX and components of the ESCRT machinery to ensure proper abscission. Dysregulation of CEP55 is linked to genomic instability, mitotic errors, and cancer progression, with overexpression observed in various tumors, correlating with poor prognosis.
CEP55 antibodies are essential tools for studying its biological roles. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect CEP55 expression, subcellular localization, and interaction partners. These antibodies aid in exploring CEP55's oncogenic potential, including its role in promoting tumor proliferation, metastasis, and therapy resistance. Commercial CEP55 antibodies are typically raised against specific epitopes, with validation in knockout controls to ensure specificity. Research applications extend to investigating CEP55 as a potential cancer biomarker or therapeutic target, particularly in malignancies exhibiting chromosomal instability. Recent studies also examine its involvement in non-mitotic processes, such as membrane trafficking and cellular signaling pathways.